CStone Pharmaceuticals Announces Completion of HK\$1.05 Billion Share Placing to Fund R&D Pipeline

CStone Pharmaceuticals (Stock Code: 2616), a leading growth-stage biotechnology company, has completed a significant share placing to raise funds for its ambitious research and development (R&D) programs. The company placed 118,000,000 new shares under its general mandate, raising net proceeds of approximately HK\$1,053.17 million after commissions and related expenses. The placing was coordinated and managed by a sole overall coordinator, placing agent, and bookrunner.

Key Points for Investors

• Placing Details:
  • Completion date: April 22, 2026
  • Shares placed: 118,000,000
  • Placing Price: HK\$8.97 per share (representing a 7.3% discount to the five-day average closing price of HK\$9.676)
  • Placed to: Not less than six professional or institutional investors, all independent third parties
  • Shares placed represented approximately 7.40% of the enlarged share capital
  • No public offering in the United States or other restricted jurisdictions
• Use of Proceeds:
  • 90% of the net proceeds are earmarked for R&D relating to “Pipeline 2.0” assets:
  • CS2009: A trispecific antibody targeting PD-1, VEGFA, and CTLA-4, currently in Phase II clinical trials with 15 cohorts. Potential first wave of Phase III multi-regional clinical trials (MRCTs) expected to initiate by end of 2026.
  • CS5001: A clinical-stage ROR1 ADC, undergoing Phase Ib clinical trial (monotherapy and combination therapy).
  • CS5007: EGFR/HER3 ADC, expected to enter IND in June 2026, with Phase I dose escalation studies to commence.
  • Other proprietary ADCs and multi-specific antibodies for immunology and inflammation diseases.
  • 10% allocated for general corporate purposes (staff costs, rental expenses, etc.)
• Unutilized Proceeds from Previous Placings:
  • July 2025 placing: 100,000,000 shares at HK\$4.72 per share, net proceeds of HK\$467.28 million. As of March 31, 2026, HK\$432.45 million remains unutilized.
  • April 2025 placing: Net proceeds of HK\$232.29 million, fully utilized as of March 31, 2026.
• Allocation of July 2025 Unutilized Proceeds:
  • 73% (HK\$315.69 million) for R&D of CS2009 and CS5001
  • 17% (HK\$73.52 million) for preclinical assets
  • 10% (HK\$43.25 million) for general corporate purposes
• Shareholding Structure Changes:
  • WuXi Healthcare Management, LLC: 10.88% (down from 11.74%)
  • Pfizer Inc.: 7.27% (down from 7.85%)
  • GIC Private Limited: 5.47% (down from 5.90%)
  • Other Shareholders: 67.46% (down from 72.85%)
  • The Placees: New holding of 7.40%
  • Total enlarged issued share capital: 1,594,239,783 shares (up from 1,476,226,451)
• Financial Position and Outlook:
  • Revenue for 2025: RMB269.6 million (RMB78.3 million from product sales, RMB167.7 million from license fees)
  • Net cash used in operating activities in 2025: Over RMB300 million, highlighting substantial working capital requirements
  • The company may seek further financing as needed, depending on clinical progress, licensing, competition, regulatory changes, and business conditions
• Price-Sensitive Information:
  • Significant capital raised for ongoing R&D efforts, especially in “Pipeline 2.0”, which includes potential blockbuster assets. The successful completion and allocation of these funds could materially impact the company’s value proposition.
  • Shareholding dilution: Existing shareholders will see their percentage holdings decrease, as new shares have been issued.
  • Clinical progress and expansion: The initiation of Phase III MRCTs for CS2009 and further development of CS5001 and CS5007 may be critical catalysts for share price movement.
  • Disclaimer regarding product development: There is no assurance that any pipeline asset will be successfully developed, marketed, or commercialized.

Additional Information for Shareholders

• The placing was conducted to support the company’s growing R&D needs, given its high cash burn and working capital requirements.
• The Board comprises Dr. Wei Li (Chairman), Dr. Jianxin Yang (Executive Director), Mr. Kenneth Walton Hitchner III, Mr. Edward Hu (Non-Executive Directors), and Mr. Kenneth Howard Jarrett, Ms. Fang Xie, Ms. Catherine Yen (Independent Non-Executive Directors).
• Investors are advised to exercise caution due to risks inherent in clinical trials and biotechnology product development.

Conclusion

This share placing represents a major funding event for CStone Pharmaceuticals, directly supporting its strategy to advance key assets in its “Pipeline 2.0”. The successful completion and allocation of proceeds have significant implications for the company’s future growth, clinical milestones, and shareholder value. However, investors should be mindful of dilution, ongoing cash requirements, and risks associated with clinical and commercial success.

Disclaimer: The information contained in this article is for informational purposes only and does not constitute investment advice. There is no assurance that CStone Pharmaceuticals will be able to successfully develop, market, or commercialize any pipeline products. Investors should exercise caution and perform their own due diligence before making any investment decisions.

View CSTONE PHARMA-B Historical chart here